Nora Balint-Lahat
Overview
Explore the profile of Nora Balint-Lahat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montagna G, Laws A, Ferrucci M, Mrdutt M, Sun S, Bademler S, et al.
J Clin Oncol
. 2024 Nov;
43(7):810-820.
PMID: 39509672
Purpose: The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management is not...
2.
Bar-Hai N, Ben-Yishay R, Arbili-Yarhi S, Herman N, Avidan-Noy V, Menes T, et al.
Front Oncol
. 2024 Oct;
14:1470379.
PMID: 39469640
Cellular plasticity is enhanced by dedifferentiation processes such as epithelial-mesenchymal transition (EMT). The dynamic and transient nature of EMT-like processes challenges the investigation of cell plasticity in patient-derived breast cancer...
3.
Ben-Yishay R, Globus O, Balint-Lahat N, Arbili-Yarhi S, Bar-Hai N, Bar V, et al.
Cells
. 2024 Sep;
13(17.
PMID: 39273076
Epithelial-to-mesenchymal transition (EMT) plays a major role in breast cancer progression and the development of drug resistance. We have previously demonstrated a trans-differentiation therapeutic approach targeting invasive dedifferentiated cancer cells....
4.
Faermann R, Sklair-Levy M, Shalmon A, Halshtok Neiman O, Gotlieb M, Yagil Y, et al.
Int J Radiat Oncol Biol Phys
. 2024 Feb;
119(5):1464-1470.
PMID: 38401856
Purpose: The aim of this study was to evaluate the rate of axillary node-positive disease in patients with early breast cancer who had a suspicious axillary lymph node on radiation...
5.
Narunsky-Haziza L, Sepich-Poore G, Livyatan I, Asraf O, Martino C, Nejman D, et al.
Cell
. 2022 Sep;
185(20):3789-3806.e17.
PMID: 36179670
Cancer-microbe associations have been explored for centuries, but cancer-associated fungi have rarely been examined. Here, we comprehensively characterize the cancer mycobiome within 17,401 patient tissue, blood, and plasma samples across...
6.
Perry G, Dadiani M, Kahana-Edwin S, Pavlovski A, Markus B, Hornung G, et al.
Mol Carcinog
. 2022 Sep;
61(11):1056-1070.
PMID: 36111610
Abnormal molecular processes occurring throughout the genome leave distinct somatic mutational patterns termed mutational signatures. Exploring the associations between mutational signatures and clinicopathological features can unravel potential mechanisms driving tumorigenic...
7.
Safran M, Masoud R, Sultan M, Tachlytski I, Chai Gadot C, Pery R, et al.
Cells
. 2022 May;
11(10).
PMID: 35626751
Liver fibrosis (LF) is a major cause of morbidity and mortality worldwide. Hepatic stellate cells (HSCs) are the primary source of extracellular matrix in the liver and their activation is...
8.
Friedman G, Levi-Galibov O, David E, Bornstein C, Giladi A, Dadiani M, et al.
Nat Cancer
. 2022 Feb;
1(7):692-708.
PMID: 35122040
Tumors are supported by cancer-associated fibroblasts (CAFs). CAFs are heterogeneous and carry out distinct cancer-associated functions. Understanding the full repertoire of CAFs and their dynamic changes as tumors evolve could...
9.
Baram T, Erlichman N, Dadiani M, Balint-Lahat N, Pavlovski A, Meshel T, et al.
Cells
. 2021 Jul;
10(6).
PMID: 34201054
Triple-negative breast cancer (TNBC) is primarily treated via chemotherapy; in parallel, efforts are made to introduce immunotherapies into TNBC treatment. CD4+ TNFR2+ lymphocytes were reported as Tregs that contribute to...
10.
Brzezinski R, Levin-Kotler L, Rabin N, Ovadia-Blechman Z, Zimmer Y, Sternfeld A, et al.
Sci Rep
. 2020 Sep;
10(1):15532.
PMID: 32968123
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of progressive liver pathologies, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. A liver biopsy is currently required to...